Why Do Schizophrenic Patients Refuse to Take Their Drugs?

Putten, Theodore Van

doi:10.1001/archpsyc.1974.01760130049008

Cited by 549 publications

(174 citation statements)

References 26 publications

Supporting

Mentioning

158

Contrasting

Unclassified

Order By: Relevance

“…Similar findings have been reported by Hoge et al and Marder and co-workers (23,31,32). These findings, together with the study by Van Putten (33), suggest that some patients may refuse antipsychotic medication in order to experience ego-syntonic, grandiose psychoses. An alternative possibility is that patients who experience grandiosity may have difficulty accepting the notion that they need help.…”

Section: Characteristics Of Patients Who Refuse Treatmentsupporting

confidence: 85%

Prospective study of patients' refusal of antipsychotic medication under a physician discretion review procedure

Kasper

Hoge²,

Feucht‐Haviar³

et al. 1997

AJP

View full text Add to dashboard Cite

Section: Characteristics Of Patients Who Refuse Treatmentsupporting

confidence: 85%

Prospective study of patients' refusal of antipsychotic medication under a physician discretion review procedure

Kasper

Hoge²,

Feucht‐Haviar³

et al. 1997

AJP

View full text Add to dashboard Cite

“…[30][31][32] Patients that experience side effects are less likely to take their medications as prescribed. 33 This is particularly true for side effects that are uncomfortable to the patient and result in dysphoric responses. Van Putten and colleagues also found that mild side effects, such as mild subjective akathisia, could result in poor compliance when patients experience discomfort every waking hour.…”

Section: Discussionmentioning

confidence: 99%

“…Van Putten and colleagues also found that mild side effects, such as mild subjective akathisia, could result in poor compliance when patients experience discomfort every waking hour. 33 There is a general notion that unwanted side effects have a negative influence on compliance. 34,35 .Also there are reports that some patients discontinue prescribed neuroleptic medicines because of side effects such as sexual dysfunction, sedation, or extra pyramidal symptoms.…”

Section: Discussionmentioning

confidence: 99%

Factors affecting adherence in patients with schizophrenia

2016

View full text Add to dashboard Cite

INTRODUCTIONSchizophrenic illnesses are typically long term illnesses. Nonadherence to medication can lead to relapse, which can mean more visits to the emergency room, rehospitalizations and increased need for clinician intervention -all of which lead to increased costs to healthcare systems. 1Rates of non-compliance in psychotic disorders have been reported to vary from 11 to 80% and in most of the cases it would result in relapse.2,3 Nonadherent patients have an average risk of relapse that is 3.7 times greater than that of adherent patients. 4 As per World Health Organization (WHO) estimates the median treatment gap for schizophrenia, including other non-affective psychosis, was 32.2 % and so the poor adherence results in wastage and under utilization of already limited treatment resources and compounds the challenges of improving health in poor populations. 5 Weiden and Olfson found that nonadherence in schizophrenia accounted for about 40% of the annual costs of rehospitalization.6 Johnson et al, reported that patients with schizophrenia who experienced a relapse did not return to their pre relapse level of social adjustment 1 year after recovery, implying that the cost of relapse is much greater than just the cost of rehospitalization.7 The cost of relapse may be particularly severe for patients with jobs and family responsibilities since they have the most to lose. Knowledge of how to improve adherence ABSTRACT Background: Nonadherence with medication regimens is among the most common causes of psychotic relapse and the need for rehospitalisation. This study was designed to look into the factors affecting attitude towards medication adherence in Schizophrenia and its relationship with severity of illness, side effects of medication. Methods: Adult males and females in the age range of 18-55 years fulfilling criteria for schizophrenia according to ICD -10, DCR, and reporting at outpatient department were taken up for this study. Severity of illness was assessed by Brief Psychiatric Rating Scale (BPRS), Side effects to medication were assessed by Udvalg for Kliniske Undersogelser (UKU) side effect scale, and Adherence was assessed by Medication adherence rating scale (MARS). Results: Adherence negatively correlated with severity of illness, and side effects in the form of increased sleep duration, asthenia, increased fatigability, lassitude and diminished sexual desire. Regression analysis with MARS as dependent variable showed side effects of medication in the form of increased sleep duration in followed by asthenia, lassitude, and increased fatigability to be predictors of poor adherence in the sample. Conclusions: Poor adherence is associated with severity of schizophrenia, sedation and asthenia like side effects due to medication. Sedation and asthenia like side effects caused a decline in adherence.

show abstract

“…The paucity of such side effects as EPS, akathisia, sexual dysfunction, and weight gain, which are leading sources of noncompliance in schizophrenia (Van Putten 1974;Young et al 1986;Pfeiffer et al 1991;Silverstone et al 1988), is encouraging, particularly if this is maintained with long-term ziprasidone treatment. Thus, the over-all safety and tolerability profile evidenced in the study seems favorable.…”

Section: Discussionmentioning

confidence: 99%

Ziprasidone 80 mg/day and 160 mg/day in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder A 6-Week Placebo-Controlled Trial

Daniel

1999

Neuropsychopharmacology

352

157

View full text Add to dashboard Cite

is a novel antipsychotic with high affinity for dopamine D 2 and D 3 , serotonin 5HT 2A , 5HT 2C , and 5HT 1D receptors and high affinity for the 5HT 1A receptor, where it acts as a potent agonist (Seeger et al. 1995) (Table 1).Ziprasidone moderately inhibits 5HT and norepinephrine re-uptake into nerve terminals, has relatively modest affinity for histamine H 1 and adrenergic ␣ 1 receptors, low affinity for dopamine D 1 and ␣ 2 receptors, and negligible affinity for M 1 receptors.In vitro functional dopamine receptor antagonism by ziprasidone has been demonstrated by concentrationdependent blockade of effects induced by a D 2 agonist, quinpirole (inhibition of forskolin-stimulated adenylate cyclase) (Seeger et al. 1995). After systemic administration, ziprasidone produced relatively modest increases in dopamine metabolites as compared with haloperidol (Seeger et al. 1995).

show abstract

Why Do Schizophrenic Patients Refuse to Take Their Drugs?

Cited by 549 publications

References 26 publications

Prospective study of patients' refusal of antipsychotic medication under a physician discretion review procedure

Prospective study of patients' refusal of antipsychotic medication under a physician discretion review procedure

Factors affecting adherence in patients with schizophrenia

Ziprasidone 80 mg/day and 160 mg/day in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder A 6-Week Placebo-Controlled Trial

Contact Info

Product

Resources

About